Literature summary for 1.1.3.15 extracted from

Zabaleta, N.; Barberia, M.; Martin-Higueras, C.; Zapata-Linares, N.; Betancor, I.; Rodriguez, S.; Martinez-Turrillas, R.; Torella, L.; Vales, A.; Olaguee, C.; Vilas-Zornoza, A.; Castro-Labrador, L.; Lara-Astiaso, D.; Prosper, F.; Salido, E.; Gonzalez-Aseguinolaza, G.; Rodriguez-Madoz, J.R.
CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I (2018), Nat. Commun., 9, 5454 .

Search for more literature for 1.1.3.15

Application

Application	Comment	Organism
medicine	application of oan in vivo CRISPR/Cas9-mediated substrate reduction therapy to treat primary hyperoxaluria type I that results in excessive hepatic oxalate production causing end-stage renal disease. A single systemic administration of an AAV8-CRISPR/Cas9 vector targeting glycolate oxidase, prevents oxalate overproduction and kidney damage, with no signs of toxicity in Agxt1-/- mice	Mus musculus

Organism

Organism	UniProt	Comment	Textmining
Mus musculus	Q9WU19	-	-

Synonyms

Synonyms	Comment	Organism
HAO1	-	Mus musculus

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)